DEXCOM Stock Gains Momentum, Receives Positive Rating Upgrade
December 7, 2023
☀️Trending News
DexCom, a leading medical device company in the diabetes space, has seen its stock gain significant momentum in recent weeks. Recently, the stock received an upgraded Relative Strength Rating, demonstrating its strength. The upgraded rating is a testament to the company’s impressive track record of successes and growth. DEXCOM ($NASDAQ:DXCM) has long been at the forefront of technology in the diabetes space, creating products that help people with diabetes to better manage their condition. Their innovative technology has enabled them to become a leader in the industry, and their stock has been steadily growing over the years.
With this recent upgrade to their Relative Strength Rating, investors are recognizing the company’s success and potential for future growth as well. Overall, this positive rating upgrade is a sign of DEXCOM’s success and the potential for further growth. As the world continues to recognize the importance of diabetes management and healthcare technology, DEXCOM is well positioned to continue its success and positive stock momentum.
Market Price
On Tuesday, DEXCOM stock opened at $116.4 and closed at $117.2, a 0.9% decrease from the prior closing price of 118.2. Despite the slight dip, analysts are positive about its momentum. Several brokerage firms have recently upgraded their ratings for DEXCOM. Evercore ISI raised its rating for DEXCOM from “in-line” to “outperform” and SunTrust Robinson Humphrey raised its rating from “neutral” to “buy”. Analysts are particularly bullish on the company’s strong technology and pipeline prospects.
Additionally, analysts believe that the company’s recent investments in research and development and acquisitions will benefit the company in the longer-term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dexcom. DEXCOM_Stock_Gains_Momentum_Receives_Positive_Rating_Upgrade”>More…
| Total Revenues | Net Income | Net Margin |
| 3.4k | 377 | 11.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dexcom. DEXCOM_Stock_Gains_Momentum_Receives_Positive_Rating_Upgrade”>More…
| Operations | Investing | Financing |
| 747.4 | -1.12k | 312.3 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dexcom. DEXCOM_Stock_Gains_Momentum_Receives_Positive_Rating_Upgrade”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.6k | 4.33k | 5.87 |
Key Ratios Snapshot
Some of the financial key ratios for Dexcom are shown below. DEXCOM_Stock_Gains_Momentum_Receives_Positive_Rating_Upgrade”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 23.2% | 19.5% | 18.1% |
| FCF Margin | ROE | ROA |
| 14.7% | 17.7% | 5.9% |
Analysis
At GoodWhale, we believe that analyzing the fundamentals of a company is key to understanding its potential. With this in mind, we have taken a look at DEXCOM to assess its current standing. The Star Chart reveals that DEXCOM is strong in terms of assets, growth and profitability, while its dividend yield is comparatively weaker. Moreover, DEXCOM has a high health score of 10/10 in terms of its cashflows and debt, which suggests that it is well-positioned to sustain future operations even in times of crisis. We have also classified DEXCOM as a ‘gorilla’ – a type of company we deem as having achieved a stable and high revenue or earning growth due to their strong competitive advantage. In light of this, we believe that DEXCOM may be of particular interest to investors who are looking for a reliable source of income and those seeking steady growth over the long term. More…
Peers
The company was founded in 1999 and is headquartered in San Diego, California. DexCom has a market cap of $15.8 billion as of May 2020. The company’s competitors include Abbott Laboratories, Insulet Corp, and Medtronic PLC.
– Abbott Laboratories ($NYSE:ABT)
Abbott Laboratories is a publicly traded healthcare company with a market capitalization of $173.42 billion as of 2022. The company’s return on equity is 16.7%. Abbott Laboratories is a diversified healthcare company that develops and manufactures a wide range of products and services for the treatment of various medical conditions. The company’s product portfolio includes pharmaceuticals, diagnostics, medical devices, and nutritional products. Abbott Laboratories has a strong presence in both developed and emerging markets.
– Insulet Corp ($NASDAQ:PODD)
Insulet Corporation is a medical device company that manufactures and sells insulin delivery systems for people with diabetes. The company was founded in 2000 and is headquartered in Massachusetts, United States. Insulet Corporation has a market capitalization of 20.48 billion as of 2022 and a return on equity of 8.72%. The company’s products include the OmniPod insulin pump, the PodderPrep insulin pump starter kit, and the mylife Pods insulin pump cartridges.
– Medtronic PLC ($NYSE:MDT)
Medtronic PLC is a medical device company that focuses on providing treatments for cardiovascular diseases, diabetes, and neurological disorders, among others. As of 2022, the company has a market cap of 105.39B and a return on equity of 7.49%. Medtronic PLC is headquartered in Dublin, Ireland.
Summary
Investment analysis of DexCom (DXCM) stock has recently seen a significant upgrade. This is a positive sign for investors, as it indicates the stock has good momentum and could be a good option for an investment portfolio. Looking ahead, investors should keep an eye on any upcoming news from DexCom, such as earnings reports or product developments, which could impact its stock price in the short-term. Additionally, analyzing the stock’s chart and seeing its historical performance, dividend payout, and other financial metrics may give investors a better understanding of whether DexCom is a good stock to buy or sell.
Related Posts
Recent Posts
